Pharmafile Logo

long-term condition

- PMLiVE

QiC Diabetes awards 2022 celebrate UK healthcare excellence

The annual awards recognise the efforts of NHS teams and individuals

- PMLiVE

Merck to donate Sudan Ebola virus vaccine to International AIDS Vaccine Initiative

Around 50,000 doses are expected to be provided for further clinical research use

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

Astellas to support development of Taysha’s AAV-based gene therapy programmes

The company will receive an exclusive option to license two clinical stage programmes

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

- PMLiVE

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Inizio

- PMLiVE

COVID-19’s consequences

COVID-19 vaccines might rhyme with antibiotics

- PMLiVE

Longitude Prize on Dementia launches innovator hackathons to those aiming for £1m grand prize

The prize will award a total of £4.34m for technology-based tool for people living with dementia

- PMLiVE

Millions invited to take part in UK’s largest health research programme

Eventually up to five million people will have the opportunity to join Our Future Health

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

One to two people per million are diagnosed with paroxysmal nocturnal haemoglobinuria each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links